Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Livzon Pharmaceutical Group ( (HK:1513) ) just unveiled an update.
Livzon Pharmaceutical Group Inc. has announced its 2025 first extraordinary general meeting scheduled for December 10, 2025. The meeting will address several key resolutions, including the cancellation of the Supervisory Committee, amendments to the Articles of Association, and the appointment of Ms. Wang Zhiyao as an independent non-executive Director. These changes indicate a strategic shift in the company’s governance structure, potentially impacting its operational efficiency and stakeholder engagement.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the development, production, and sale of pharmaceutical products, catering to various medical needs in the market.
YTD Price Performance: 20.79%
Average Trading Volume: 1,341,695
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.3B
See more insights into 1513 stock on TipRanks’ Stock Analysis page.